Efgartigimod Alfa · Vyvgart

Antibody fragment

Also known as ARGX-113

Approvedregulatory verdict

Evidence outlook

Approved: Generalized Myasthenia Gravis, Myasthenia Gravis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Chronic Inflammatory Demyelinating Polyneuropathy

Also approved (2)
EU
  • Vyvgart is indicated as- an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are antiacetylcholine receptor (AChR) antibody positive.- monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
Product first approved 2022EMA
JP
  • Treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants)
Product first approved 2022PMDA
Featured evidence outside this drug's tracked markets:FACT (NCT06497374) · Neuromyelitis Optica · Phase 2 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Generalized Myasthenia Gravis
NCT03770403 · argenx
2019-03-01 – 2022-06-30 · Generalized Myasthenia Gravis
What this study did
Phase 2 (8)
Myasthenia Gravis
NCT06221501 · Shanghai Zhongshan Hospital
2024-02-01 – 2027-06-30 · Myasthenia Gravis
What this study did
Other / comorbidity
NCT07822776 · Beijing Tongren Hospital
2026-06-25 – 2028-03-30 · Encephalitis Autoimmune
What this study did
NCT07806916 · Beijing Tiantan Hospital
2026-09 – 2027-12 · Guillain-Barré Syndrome
What this study did
NCT06497374 · Tianjin Medical University General Hospital
2024-07-05 – 2026-06-30 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
What this study did
NCT05701189 · Chafic Karam
2024-09-10 – 2026-02-20 · Guillain-Barre Syndrome
What this study did
NCT03334058 · argenx
2017-10-18 – 2020-10-28 · Pemphigus Vulgaris, Pemphigus Foliaceus
What this study did
NCT03102593 · argenx
2017-03-13 – 2019-04-09 · Primary Immune Thrombocytopenia
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07011589 · M. Peter Marinkovich
2026-07 – 2028-01 · Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
What this study did
Phase 1 (2)
Other / comorbidity
NCT03334084 · argenx
2017-10-11 – 2018-09-19 · Bioavailability Study
What this study did
NCT03457649 · argenx
2015-09-09 – 2017-02-21 · Healthy Volunteers
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Efgartigimod Alfa (Vyvgart): this drugStage not on recordAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
RiliprubartPhase 3Monoclonal antibodyComplement C1snot yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
TAK-411
—(overall)
Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vyvgart (Efgartigimod Alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Myasthenia GravisNot yet recruiting
Est. primary completion 2026-12-30 · NCT06221501 · CT.gov ↗
What to watch
2027 (2)
June 2027 (1)
Phase 2Guillain-Barré SyndromeNot yet recruiting
Est. primary completion 2027-06 · NCT07806916 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Encephalitis AutoimmuneRecruiting
Est. primary completion 2027-12-31 · NCT07822776 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 1/2Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis BullosaNot yet recruiting
Est. primary completion 2028-01 · NCT07011589 · CT.gov ↗
What to watch

See the full readout calendar ↗